kcl

RS 57639 is a bioactive chemical.

β-NETA (α-NETA) is a stable, noncompetitive, slowly reversible choline acetyltransferase (ChAT) inhibitor with an IC50 of 9 μM and is a potent chemokine-like receptor-1 (CMKLR1) antagonist. β-NETA has anti-cancer activity[1][2]. β-NETA weakly inhibits cholinesterase (IC50=84 µM) and acetylcholinesterase (IC50=300 µM).

KCL-286 is an orally available and potent retinoic acid receptor beta agonist for the amelioration of spinal cord injury (SCI).

KCL-HO-1i is an orally active heme oxygenase-1 (HO-1) inhibitor with an IC50 of 123 nM for rat HO-1 and 128 nM for human HO-1. It targets immune-suppressive LYVE-1+ perivascular tumor-associated macrophages (PvTAMs) in the tumor microenvironment (TME) and reduces PvTAM-mediated immune evasion. In MMTV-PyMT mice with spontaneous breast cancer or C57Bl/6 mice with subcutaneous MN-MCA1 sarcoma, KCL-HO-1i demonstrates synergistic anti-tumor effects when combined with chemotherapy. It is applicable for cancer research.

ZT-1a is a SPAK inhibitor.ZT-1a inhibits SPAK.ZT-1a can be used for the prevention and treatment of neurodegenerative and neurocognitive disorders.

Bumetanide (PF 1593) is a potent sulfamoylanthranilic acid derivative belonging to the class of loop diuretics. In the brain, bumetanide may prevent seizures in neonates by blocking the bumetanide-sensitive sodium-potassium-chloride cotransporter (NKCC1), thereby inhibiting chloride uptake thus, decreasing the internal chloride concentration in neurons and may block the excitatory effect of GABA in neonates.

Torsemide (AC-4464) is an anilinopyridine sulfonylurea belonging to the class of loop diuretics. Torsemide has a prolonged duration of action compared to other loop diuretics, is extensively protein bound in plasma and has a relatively long half-life.

Sodium dichloroacetate (BCA) , a specific inhibitor of pyruvate dehydrogenase kinase (PDK) with IC50 values of 183 and 80 μM for PDK2 and PDK4 respectively, has been shown to derepress a mitochondrial potassium-ion channel axis, trigger apoptosis in cancer cells, and inhibit tumor growth.

GLUT4-IN-2 is a specific GLUT4 inhibitor that inhibits GLUT1 and GLUT4.GLUT4-IN-2 has antitumor activity, induces apoptosis and cell cycle arrest, and can be used for cancer research.

Furosemide is a potent NKCC2 (Na-K-2Cl symporter) inhibitor, used for edema and chronic renal insufficiency.

Azosemide is a potent NKCC1 inhibitor (IC50s: 0.246 µM and 0.197 µM for hNKCC1A and NKCC1B).

Bumetanide-D5 is a deuterium-labeled Bumetanide. Bumetanide (T0108) is a Na+-K+-Cl- (NKCC1) inhibitor (IC50s: 0.68 and 4.0 μM for hNKCC1A and hNKCC2A).

Piretanide, an orally active loop diuretic, is recognized as a relatively safe and effective pharmacological agent with notable diuretic capacity. Piretanide exhibits potential for research in the treatment of congestive heart failure, with a distinct advantage due to its potassium-sparing properties that may reduce electrolyte imbalance. Piretanide can also be applied within experimental frameworks directed at the study of hypertension, further supporting its utility in cardiovascular research models.

Compound 2, known as KCC2 potentiators-1, acts as an enhancer of the potassium chloride cotransporter-2 (KCC2). It holds potential for applications in studies related to neurological disorders.

Furosemide sodium (Frusemide Sodium) is a potent and orally active inhibitor of Na+/K+/2Cl- (NKCC) cotransporter, NKCC1 and NKCC2. Furosemide sodium is also a GABAA receptors antagonist and displays 100-fold selectivity for α6-containing receptors than α1-containing receptors. Furosemide sodium acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema.

Bumetanide sodium is a potent loop diuretic that acts as a blocker for the sodium-potassium-chloride cotransporter (NKCC). It selectively inhibits NKCC1 and NKCC2, with IC50 values of 0.68 μM and 4.0 μM for hNKCC1A and hNKCC2A, respectively [1] [2].

ARN23746 (IAMA-6) is a selective NKCC1 inhibitor with neuroprotective activity, used in the research of brain diseases including drug-resistant epilepsy (such as temporal lobe epilepsy TLE, Dravet syndrome DrS), autism spectrum disorder ASD, and Down syndrome DoS.

ERK-CLIPTAC is a PROTAC (PROteolysis TArgeting Chimera) molecule designed to induce the degradation of Extracellular signal-Regulated Kinase (ERK) [1].

Furosemide-D5 is a deuterium marker for Furosemide (T0837) and can be used in isotope tracer experiments.Furosemide is a potent and orally active inhibitor of Na+/K+/2Cl- (NKCC), NKCC1, and NKCC2 cotransporter proteins and GABAA receptor antagonist and is used as diuretic reagent, congestive heart failure, hypertension and edema.

Bumetanide (Standard) is the standard substance of Bumetanide, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Bumetanide (PF 1593) is a potent sulfamoylanthranilic acid derivative belonging to the class of loop diuretics. In the brain, bumetanide may prevent seizures in neonates by blocking the bumetanide-sensitive sodium-potassium-chloride cotransporter (NKCC1), thereby inhibiting chloride uptake thus, decreasing the internal chloride concentration in neurons and may block the excitatory effect of GABA in neonates.

Torsemide (Standard) is the standard substance of Torsemide, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Torsemide (AC-4464) is an anilinopyridine sulfonylurea belonging to the class of loop diuretics. Torsemide has a prolonged duration of action compared to other loop diuretics, is extensively protein bound in plasma and has a relatively long half-life.

Lecozotan HCl (SRA-333) is a potent and selective 5-HT antagonist that significantly enhances KCl-stimulated glutamate and acetylcholine release from the hippocampal dentate gyrus and has cognitive enhancing properties. Chronic administration of Lecozotan HCl did not induce 5-HT(1A) receptor tolerance or desensitization in a behavioral model demonstrating 5-HT(1A) receptor function.

Oxodipine, a dihydropyridine-type calcium antagonist, inhibited KCl-induced aortic contraction in rabbits and reduced cardiac force in less potent rat ventricular test-paper contractions. In rat cultured neonatal ventricular myocytes, Oxodipine reduced L-type Ca currents (I) with an IC of 0.24 μM, and against T-type Ca currents (I) with an IC of 0.41 μM. Oxodipine causes constipation in mice and gingival hyperplasia in dogs.

Harmalol hydrochloride (Harmidol hydrochloride) is a β-carboline alkaloid that can be extracted from the seeds of Peganum harmala L. Harmalol hydrochloride is the major metabolite of Harmaline and significantly inhibits dioxin-mediated induction of CYP1A1 at both transcriptional and post-translational levels. Harmalol hydrochloride showed vasorelaxant activity in isolated rat thoracic aortic preparations preconstricted with phenylephrine or KCl. Harmalol hydrochloride has antioxidant activity.